Administration of a third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell (CAR-T) therapy appeared feasible and showed no major safety concerns for patients with CD19-positive relapsed or refractory lymphoid malignancies. The initial results of the Heidelberg CAR trial 1 (HD-CAR-1) were presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida.

Unlike second-generation CAR-T therapies, which have either a 4-1BB or CD28  costimulatory domain, third-generation CAR-T therapies appear to incorporate 2 or more signaling domains. Two other clinical trials (one of which is Identifier: NCT02132624) have evaluated third-generation anti-CD19 CAR-T therapies, and have reported “favorable” results, according to the study researchers.

So far, the HD-CAR-1 trial ( Identifier: NCT03676504) has enrolled 10 patients with relapsed or refractory lymphoid disease to receive lymphodepleting therapy with fludarabine and cyclophosphamide followed by administration of anti-CD19 CAR-T.

Among these 10 patients, 3 have B-lineage acute lymphoblastic leukemia, 2 have chronic lymphocytic leukemia, 2 have mantle cell lymphoma, 2 have diffuse large B-cell lymphoma, and 1 has transformed follicular lymphoma.

To date, all enrolled patients have undergone leukapheresis and 8 have received autologous anti-CD19 CAR-T, with 6 receiving only 106 CAR-T cells and 2 receiving 5 X 106 CAR-T cells. The CAR-T cells were manufactured successfully, with no production failures.

No patients had higher than grade 2 cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. One patient required treatment with tocilizumab. No patients had neurological side effects.

To date, 6 of the 8 treated patients have responded. The remaining 2 treated patients are not evaluable for a response yet, according to the data in the abstract.

“Leukapheresis and CAR-T cell manufacturing were effective for all patients enrolled in the HD-CAR trial to date,” the study researchers wrote in the abstract. “Patients responded clinically to treatment despite low numbers of administered CAR-T cells.”

Read more of Cancer Therapy Advisor‘s coverage of ASH’s annual meeting by visiting the conference page.

Schubert M-L, Schmitt A, Neuber B, et al. Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients. Presented at: 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7-10, 2019: Orlando, Florida. Abstract 51. is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.

European car2

Piston Rings, Window Switch, Oxygen Sensor, Ignition Coil - Haoyang,